title: Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma.
abstract: OBJECTIVE
  Different remission rates of gastric low-grade, B-cell, mucosa-associated lymphoid tissue (MALT) lymphoma have been reported after Helicobacter pylori eradication. We assessed the long-term remission and relapse rates of early stage MALT lymphoma in patients treated only by H pylori eradication and identified factors that might predict outcome.
  
  
  METHODS
  This systematic review analyzed data from 32 studies, including 1408 patients.
  
  
  RESULTS
  The MALT lymphoma remission rate was 77.5% (95% confidence interval, 75.3-79.7), and was significantly higher in patients with stage I than stage II(1) lymphoma (78.4% vs 55.6%; P = .0003) and in Asian than in Western groups (84.1% vs 73.8%; P = .0001). Neoplasia confined to the submucosa regressed more frequently than that with deeper invasion (82.2% vs 54.5%; P = .0001); patients with lymphoma localized to the distal stomach experienced regression more frequently than those with lymphoma of the proximal stomach (91.8% vs 75.7%; P = .0037). The remission rate was higher among patients without the API2-MALT1 translocation than in those with this translocation (78% vs 22.2%; P = .0001). In an analysis of data from 994 patients, 7.2% experienced lymphoma relapse during 3253 patient-years of follow-up evaluation, with a yearly recurrence rate of 2.2%. Infection and lymphoma were cured by additional eradication therapy in all patients with H pylori recurrence (16.7%). Five (0.05%) of the patients initially cured of lymphoma developed high-grade lymphoma within 6 to 25 months of therapy.
  
  
  CONCLUSIONS
  H pylori eradication is effective in treating approximately 75% of patients with early stage gastric lymphoma. Long-term follow-up evaluation of these patients is needed to detect early lymphoma relapse or progression.
authors.affiliation: Gastroenterology and Digestive Endoscopy, Nuovo Regina Margherita Hospital, Rome, Italy. zullo66@yahoo.it
authors.forename: Angelo
authors.initials: A
authors.lastname: Zullo
authors.forename: Cesare
authors.initials: C
authors.lastname: Hassan
authors.forename: Francesca
authors.initials: F
authors.lastname: Cristofari
authors.forename: Alessandro
authors.initials: A
authors.lastname: Andriani
authors.forename: Vincenzo
authors.initials: V
authors.lastname: De Francesco
authors.forename: Enzo
authors.initials: E
authors.lastname: Ierardi
authors.forename: Silverio
authors.initials: S
authors.lastname: Tomao
authors.forename: Manfred
authors.initials: M
authors.lastname: Stolte
authors.forename: Sergio
authors.initials: S
authors.lastname: Morini
authors.forename: Dino
authors.initials: D
authors.lastname: Vaira
mesh_terms: D005753:Gastric Mucosa / Q000473:pathology*; D016481:Helicobacter Infections / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D008223:Lymphoma / Q000150:complications* / Q000473:pathology*; D012008:Recurrence; D013274:Stomach Neoplasms / Q000150:complications* / Q000473:pathology*; D016896:Treatment Outcome